Wall Street Zen Upgrades Grace Therapeutics (NASDAQ:GRCE) to Hold

Grace Therapeutics (NASDAQ:GRCE) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Grace Therapeutics Price Performance

Shares of NASDAQ:GRCE opened at $3.15 on Friday. The business’s fifty day moving average price is $3.15 and its two-hundred day moving average price is $2.81. Grace Therapeutics has a fifty-two week low of $1.75 and a fifty-two week high of $4.97. The stock has a market capitalization of $43.56 million, a price-to-earnings ratio of -3.66 and a beta of 1.06.

Grace Therapeutics (NASDAQ:GRCE) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. Research analysts expect that Grace Therapeutics will post -1.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Grace Therapeutics

Large investors have recently made changes to their positions in the company. Millington Financial Advisors LLC acquired a new position in shares of Grace Therapeutics during the second quarter valued at $59,000. Palumbo Wealth Management LLC acquired a new position in shares of Grace Therapeutics during the second quarter valued at $144,000. Stonepine Capital Management LLC acquired a new position in shares of Grace Therapeutics during the first quarter valued at $666,000. ADAR1 Capital Management LLC acquired a new position in shares of Grace Therapeutics during the first quarter valued at $783,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of Grace Therapeutics during the first quarter valued at $2,686,000. Institutional investors and hedge funds own 6.08% of the company’s stock.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.